A Ikido Pharma Inc. AIKI
We take great care to ensure that the data presented and summarized in this overview for AIkido Pharma Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AIKI
View all-
Vanguard Group Inc Valley Forge, PA193KShares$734,8890.0% of portfolio
-
Black Rock Inc. New York, NY72.5KShares$275,5720.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny56.3KShares$214,0380.0% of portfolio
-
Geode Capital Management, LLC Boston, MA43.1KShares$163,8820.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX39.8KShares$151,3650.0% of portfolio
-
State Street Corp Boston, MA20.1KShares$76,3260.0% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX19KShares$72,2000.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il16.5KShares$62,7680.0% of portfolio
-
Ubs Group Ag11.5KShares$43,8670.0% of portfolio
-
Tower Research Capital LLC (Trc) New York, NY4.17KShares$15,8490.0% of portfolio
Latest Institutional Activity in AIKI
Top Purchases
Top Sells
About AIKI
AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.
Insider Transactions at AIKI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 18
2025
|
Anthony Hayes CEO |
BUY
Grant, award, or other acquisition
|
Direct |
500,000
+25.32%
|
-
|
|
Feb 18
2025
|
Ronald J. Lieberman Director |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+45.23%
|
-
|
|
Feb 12
2025
|
Kyle Michael Wool President |
BUY
Open market or private purchase
|
Direct |
288,184
+11.58%
|
-
|
|
Feb 10
2025
|
Robert Frederick Dudley Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+30.85%
|
-
|
|
Feb 10
2025
|
Ronald J. Lieberman Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+24.03%
|
-
|
|
Feb 10
2025
|
Ronald J. Lieberman Director |
BUY
Open market or private purchase
|
Direct |
21,613
+50.0%
|
-
|
|
Feb 10
2025
|
Tim S Ledwick Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+24.11%
|
-
|
|
Feb 10
2025
|
Tim S Ledwick Director |
BUY
Open market or private purchase
|
Direct |
8,645
+28.71%
|
-
|
|
Feb 10
2025
|
Kyle Haug Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+29.06%
|
-
|
|
Feb 10
2025
|
Kyle Haug Director |
BUY
Open market or private purchase
|
Direct |
14,409
+50.0%
|
-
|
|
Feb 10
2025
|
Christopher Franklin Devall COO |
BUY
Grant, award, or other acquisition
|
Direct |
351,851
+46.14%
|
-
|
|
Feb 10
2025
|
Christopher Franklin Devall COO |
BUY
Open market or private purchase
|
Direct |
28,818
+32.87%
|
-
|
|
Feb 10
2025
|
Gregory James Blattner Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+21.36%
|
-
|
|
Feb 10
2025
|
Gregory James Blattner Director |
BUY
Open market or private purchase
|
Direct |
14,409
+34.95%
|
-
|
|
Feb 10
2025
|
Anthony Hayes CEO |
BUY
Open market or private purchase
|
Direct |
288,184
+22.81%
|
-
|
|
Dec 31
2024
|
Kyle Michael Wool President |
BUY
Grant, award, or other acquisition
|
Direct |
309,118
+13.91%
|
-
|
|
Dec 31
2024
|
Anthony Hayes CEO |
BUY
Grant, award, or other acquisition
|
Direct |
309,118
+31.04%
|
-
|
|
Jun 11
2024
|
Kyle Michael Wool President |
BUY
Grant, award, or other acquisition
|
Direct |
154,559
+8.79%
|
-
|
|
Jun 11
2024
|
Anthony Hayes CEO |
BUY
Grant, award, or other acquisition
|
Direct |
154,559
+29.04%
|
-
|
|
May 30
2024
|
Anthony Hayes CEO |
BUY
Open market or private purchase
|
Direct |
3,482
+1.54%
|
$6,964
$2.4 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.98M shares |
|---|---|
| Open market or private purchase | 719K shares |